SFJ Pharma Ltd. II announces agreement with Pfizer to develop Axitinib
9 January 2012 | By Citigate Dewe Rogerson
SFJ announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial...
List view / Grid view
9 January 2012 | By Citigate Dewe Rogerson
SFJ announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial...
9 January 2012 | By AstraZeneca
The info was out of date planning information...
9 January 2012 | By GlaxoSmithKline
GSK and Theravance, Inc. announced the completion of the phase III registration programme...
8 January 2012 | By Novartis
There have been no related adverse events reported with the issues leading to the recall...
7 January 2012 | By Bristol-Myers Squibb
Bristol-Myers Squibb to acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger...
6 January 2012 | By The Words Workshop Ltd
GEA Pharma Systems has appointed Zósimo López Moreno...
6 January 2012 | By Merck
The U.S. FDA recently approved the use of ISENTRESS® (raltegravir) in combination with other antiretroviral (ARV) medicines...
6 January 2012 | By Gilead Sciences
Gilead Sciences, Inc. has received early termination of the required waiting period...
5 January 2012 | By Merck Millipore
Merck Millipore, announced that the division was invited to serve on the faculty of the CPIER at Peking University...
4 January 2012 | By Biogen Idec
Biogen Idec and Isis Pharmaceuticals, Inc. have entered into an exclusive, worldwide option and collaboration agreement...
4 January 2012 | By Astellas
Tivozanib has demonstrated superiority over sorafenib...
3 January 2012 | By Teva
Study findings published in Frontiers in Bioscience...
3 January 2012 | By H. Lundbeck A/S
Lundbeck announced that Onfi tablets are now available for prescribing in the United States...
1 January 2012 | By Teva
Dr. Jeremy Levin, a former Senior Executive at Bristol-Myers Squibb, to succeed Shlomo Yanai as President and CEO...
30 December 2011 | By Pfizer
First pneumococcal conjugate vaccine for adults 50+ has potential to help address high incidence of pneumococcal pneumonia...